Office of Technology Transfer – University of Michigan

Therapeutic Modulation of Signal Transduction Aberrations

Technology #2070

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Researchers
Joseph Holoshitz
Managed By
Janani Ramaswamy
Licensing Specialist, Medical Deviceses 734-763-9081
Patent Protection
US Patent Pending

Background

Several signaling pathways are involved in a wide range of physiological functions, with increasingly awareness that intercellular and intracellular signal transduction aberrations may underlie the pathogenesis of many diseases. Consequently, attempts to target such signaling abnormalities have become a common theme in the design of new therapeutic strategies. In particular, two antagonistic signaling pathways, mediated by cyclic adenosine 3',5' monophosphate (cAMP) and nitric oxide (NO) play a role in a variety of disease states including Alzheimer’s disease, polycystic kidney disease, prostate cancer, atopic dermatitis, osteoarthritis, septic shock, congestive heart failure and rheumatoid arthritis. As such, methods to counteract and reverse disease-causing signaling defects may be advantageous for various conditions.

Technology

Researchers at the University of Michigan have developed a method to treat a disease with an underlying signal transduction aberration via administration of shared epitope (SE)- or SE motif-containing peptide, which may be conjugated to a carrier molecule. In particular, such peptide has been shown to selectively activate NO-cGMP-PKG pathway with reciprocal effect on cAMP-PKA pathway. As cAMP-PKA signaling and/ or inadequate NO-cGMP response are implicated in variety of pathogeneisis, this approach may be explored for many applications, via targeted delivery. In addition, the SE motif presented here in provide neuroprotective effects of ApoE, APLP1, and laminin, and may account for the negative association between Alzheimer’s disease and rheumatoid arthritis.

Applications and Advantages

Applications

  • Treatment for disease involving aberrant NO-cGMP-PKG/ cAMP-PKA pathways including Alzheimer’s disease and rheumatoid arthritis.

Advantages

  • May be applicable to a variety of disease states, with targeted delivery.